Screener
Cytokinetics CYTK Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by Cytokinetics in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The source filing: Cytokinetics’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 4:30 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-338217
FAQ
- What is Cytokinetics's total equity?
- Cytokinetics (CYTK) reported total equity of -$173.49M in Q2 2026.
- How has Cytokinetics's total equity changed year-over-year?
- Cytokinetics's total equity increased by 52.9% year-over-year, from -$368.72M to -$173.49M.
- What is the long-term trend for Cytokinetics's total equity?
- Over 5 years (2020 to 2025), Cytokinetics's total equity has grown at a 42.2% compound annual growth rate (CAGR), from $113.38M to -$659.63M.
- What does total equity mean?
- Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.
Ask your AI about Cytokinetics's total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude